Drugs / VB19055
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07254481 | Oct 2025 → Jul 2026 overdue | hypertensive disorder | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VB19055 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07254481 ↗ |
| Route | Oral | “administered as a single or multiple oral dose” NCT07254481 ↗ |